🇺🇸 Inhibitors, ACE in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 12

Most-reported reactions

1. Heparin-Induced Thrombocytopenia — 2 reports (16.67%)
2. Ventricular Tachycardia — 2 reports (16.67%)
3. Abdominal Pain Upper — 1 report (8.33%)
4. Activated Partial Thromboplastin Time Prolonged — 1 report (8.33%)
5. Alopecia Areata — 1 report (8.33%)
6. Angioedema — 1 report (8.33%)
7. Arterial Occlusive Disease — 1 report (8.33%)
8. Arterial Thrombosis — 1 report (8.33%)
9. Asthenia — 1 report (8.33%)
10. Atrial Fibrillation — 1 report (8.33%)

Source database →

Frequently asked questions

Is Inhibitors, ACE approved in United States?

Inhibitors, ACE does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Inhibitors, ACE in United States?

National Heart, Lung, and Blood Institute (NHLBI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.